Table 4

Univariate analysis of predictors of sustained remission: exact OR and CI

N (%) achieving remissionExact OR (95% CI)p Value
Clinical features before treatment
 Female6/14 (42.9%)4.19 (0.66 to 34.73)0.158
 Male10/13 (76.9%)
Duration of symptoms before treatment (months)
 >8 months3/9 (33.3%)Reference
 6–8 months5/9 (55.6%)2.37 (0.27 to 25.52)0.294
 <6 months8/9 (88.9%)13.25 (1.00 to 825.0)0.050
Imaging data in remission
 Grey scale synovitis score <2 in all MCP/PIP/wrist joints
 No3/6 (50.0%)Reference
 Missing5/7 (71.4%)2.32 (0.16 to 44.95)0.825
 Yes8/14 (57.1%)1.31 (0.13 to 13.74)1.000
Immunological data in remission
 Naives (% of CD4+ T cells)
 <5.52/7 (28.6%)Reference
 5.5–10.03/6 (50.0%)2.32 (0.16 to 44.95)0.825
 missing4/7 (57.1%)3.04 (0.24 to 55.30)0.592
 >10.07/7 (100.0%)14.29 (1.45 to infinity)0.021
IRC (% of CD4+ T cell)
 >441/8 (12.5%)Reference
 28–446/8 (75.0%)16.20 (1.09 to 1099)0.041
 Missing3/3 (100.0%)12.27 (1.02 to infinity)0.048
 <286/8 (75.0%)16.20 (1.09 to 1099)0.041
Treg CD25highFOXP3+ (% of CD4+ T cells)
 >2.22/10 (20.0%)Reference
 1.5–2.26/9 (66.7%)7.03 (0.73 to 111.80)0.110
 Missing1/1 (100.0%)2.67 (0.07 to infinity)0.546
 <1.57/7 (100.0%)23.26 (2.54 to infinity)0.004
CD62L+ Treg (% of CD25highFOXP3+ Treg)
 <601/5 (20.0%)Reference
 60–705/6 (83.3%)13.45 (0.60 to 1175)0.134
 Missing6/11 (54.6%)4.36 (0.29 to 354.80)0.462
 >704/5 (80.0%)10.91 (0.45 to 979)0.206
  • Bold type indicates statistically significant differences.

  • IRC, inflammation-related cells; MCP, metacarpophalangeal; PIP, proximal interphalangeal; Treg, T regulatory cells.